The company joins Johnson & Johnson and Abbott as top medtech firms that expect an impact in the hundreds of millions of ...

Most readers would already know that Boston Scientific's (NYSE:BSX) stock increased by 2.0% over the past week. Given that the stock prices usually follow long-term business performance ...

Boston Scientific BSX has been gaining from new product launches and accretive acquisitions. International expansion remains a key growth driver. The stock carries a Zacks Rank #2 (Buy).

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and ...

Boston Scientific has a 12-month low of $70.97 and a 12-month high of $107.17. The business’s 50 day moving average is $98.68 and its 200-day moving average is $94.92.

Boston Scientific BSX has outperformed the market over the past 15 years by 8.98% on an annualized basis producing an average annual return of 20.36%. Currently, Boston Scientific has a market ...

13 analysts have expressed a variety of opinions on Boston Scientific BSX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick ...

Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States. In Europe, the Middle East and Africa (EMEA), Boston Scientific is ...

Though Boston Scientific brought in $4.66 billion in revenue for the first quarter of 2025, up 20.9% year over year, the medical devicemaker is bracing for a potential $200 million hit in the ...

MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to ...